reports
- Pierre Tegner
Galderma : The derma pure player is on track to more than triple EPS o...
We are initiating coverage of Galderma with an Outperform rating and a target price of CHF 197. Our positive view is based on: 1/ unique positioning on the buoyant and sophisticated dermatological market; 2/ the ramp-up phase, which is reflected in a very sharp rise in earnings (EPS x3.5 between 2025 and 2030) and 3/ an attractive valuation (2028e P/E
- Pierre Tegner
Galderma : Vers plus qu’un triplement des BPA d’ici 2030 pour le pure ...
Nous initions la couverture sur Galderma avec une opinion Surperformance et un OC de 197 CHF. Notre opinion positive repose sur : 1/ le positionnement unique sur le marché porteur des soins de la peau ; 2/ la phase de montée en puissance qui extériorise une très forte hausse des résultats (BPA x3.5 entre 2025 et 2030) et 3/ une valorisation attractive (PE 28e
LOGN LOGITECH INTERNATIONAL S.A.
AC ACCOR SA
JMT JERONIMO MARTINS SGPS S.A.
ACN ACCENTURE PLC CLASS A
RMS HERMES INTERNATIONAL SCA
CDR CD PROJEKT S.A.
OMV OMV AG
ELG ELMOS SEMICONDUCTOR SE
TPE PVA TEPLA AG
ENI ENI S.P.A.
COTN COMET HOLDING AG
CICN CICOREL HOLDING S.A.
BAYN BAYER AG
ENEL ENEL SPA
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
AIXA AIXTRON SE
PFV PFEIFFER VACUUM TECHNOLOGY AG
NEM NEMETSCHEK SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
RAA RATIONAL AG
MONC MONCLER SPA
WAF SILTRONIC AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
MELE MELEXIS NV
NOD NORDIC SEMICONDUCTOR ASA
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
JEN JENOPTIK AG
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
ARM ARM HOLDINGS PLC
GALD GALDERMA GROUP AG
ZAB ZABKA GROUP
AMS AMS-OSRAM AG
IFCN INFICON HOLDING AG
LOGN LOGITECH INTERNATIONAL S.A.
AC ACCOR SA
JMT JERONIMO MARTINS SGPS S.A.
ACN ACCENTURE PLC CLASS A
RMS HERMES INTERNATIONAL SCA
CDR CD PROJEKT S.A.
OMV OMV AG
ELG ELMOS SEMICONDUCTOR SE
TPE PVA TEPLA AG
ENI ENI S.P.A.
COTN COMET HOLDING AG
CICN CICOREL HOLDING S.A.
BAYN BAYER AG
ENEL ENEL SPA
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
AIXA AIXTRON SE
PFV PFEIFFER VACUUM TECHNOLOGY AG
NEM NEMETSCHEK SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
RAA RATIONAL AG
MONC MONCLER SPA
WAF SILTRONIC AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
MELE MELEXIS NV
NOD NORDIC SEMICONDUCTOR ASA
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
JEN JENOPTIK AG
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
ARM ARM HOLDINGS PLC
GALD GALDERMA GROUP AG
ZAB ZABKA GROUP
AMS AMS-OSRAM AG
IFCN INFICON HOLDING AG
AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From I...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD) will showcase a strong presence at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025, with two symposia, four Masterclass sessions, 11 research e-posters, and an experiential Galderma lounge alongside its interactive booth (O2, Hall Ravel) featuring five Meet-the-Expert sessions. This extensive program highlights the breadth of Galderma’s leading Injectable Aesthetics portfolio, designed to address the present and future needs of patients and healthcare professionals alike. This press release ...
Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% ...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2024, delivering strong results for another consecutive year while making significant progress with its blockbuster platforms and future growth drivers. Record net sales: Achieved 4,410 million USD in net sales, up 9.3% year-on-year on a constant currency basis1, with volume-based growth fueled by focused execution and differentiated innovation Broad-based growth: Continued performance across all product categories with constan...
AAD 2025: Galderma to Present Extensive Updates From Across Its Dermat...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma will present updates from across its broad dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7-11, 2025 in Orlando, Florida. The company will present 22 e-posters – including two oral presentations – with updates on a number of its innovative products, including Nemluvio, Sculptra, Restylane and Relfydess. These presentations combined reinforce the strength of Galderma’s growth journey, its status as the pure-play category leader in dermatology, and its innovative pipeline. “We’re bring...
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in ...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab’s subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years of age and older with a body weight of at leas...
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for ...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now approved for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.11 This press release features multimedia. View the full release...
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Lon...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of RelabotulinumtoxinA (Relfydess) to treat frown lines (glabellar lines)1. Galderma’s analysis was presented at the International Master Course on Aging Science (IMCAS) 2025 annual congress, held in Paris from January 30 to February 1, 2025. Developed and manufa...
Galderma Demonstrates Injectable Aesthetics Leadership in Medication-D...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient’s journey, as well as the first international consensus-based guidelines from global experts on how to treat this patient population. Today, at the International Master Course on Aging Science (IMCAS) 2025 annual congress, Galderma will also host a first-of-its-kind masterclass on this topic with international aesthetics experts. Titled “M...
IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launche...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 – February 1 in Paris, France. The company will share ten research e-posters with data that differentiate its injectable aesthetic products, including Relfydess (RelabotulinumtoxinA), Sculptra and Restylane. Alongside its community partners, Galderma will also host three symposia, a Masterclass, five Meet the Expert sessions, and an interactive booth focused on the power of Relfydess. ...
Galderma Premieres Positive Interim Results Demonstrating the Efficacy...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® Lyft™ or Contour™ in combination with Sculptra® in patients with medication-driven weight loss with associated facial volume loss.1 Initial three-month interim data from this first-of-its-kind trial suggest that this treatment combination effectively improved facial aesthetic appearance with high patient satisfaction.1 The results will be presented later today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Rat...
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Pa...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press rel...
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Sev...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatme...
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demo...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab monotherapy in adults with moderate-to-severe prurigo nodularis, were published in .1 The trial met both primary and all key secondary endpoints, showing that nemolizumab-treated patients had significantly higher improvements in itch and skin lesions when compared to those receiving placebo at Week 16, with a rapid and clinically meaningful response on itch and sleep disturbance observed as early as ...
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in Chi...
ZUG, Switzerland--(BUSINESS WIRE)-- This month marks the 25th anniversary of the approval of Sculptra®, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation.1-5,10-16 Sculptra works with the body’s natural processes to achieve healthier, radiant skin and a more youthful appearance, and has been a cornerstone of Galderma’s broad portfolio of proven aesthetic treatments.17,18 During its 25 years on the market, healthcare professionals have treated millions of patients with Sculptra, with distribution in over 40 countries and regions worldwide.10,12...
Galderma Brings Together Over 650 Healthcare Professionals from Asia-P...
SINGAPORE--(BUSINESS WIRE)-- Galderma (SWX:GALD), the pure-play dermatology category leader, today announced a new edition of the Galderma Aesthetic Injector Network (GAIN) event in the Asia-Pacific region, which houses some of the company’s fastest growing markets. This is the largest regional event to date and will deliver a premium and engaging experience for more than 650 delegates. Taking place October 26-27 in Incheon, South Korea, the extensive, two-day agenda will take a deep dive into the six trends identified in the ‘NEXT by Galderma’ report and explore how they will shape the future...
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Mo...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2024, reporting record net sales and significant progress across its product categories and key future growth drivers. Record net sales: Achieved 3.259 billion USD in net sales during the first nine months of 2024, up +9.2% year-on-year in constant currency1, predominantly driven by volume growth, complemented by favorable mix. Galderma also achieved the highest third quarter net sales in its history Broad-based gro...
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess™) for frown lines and crow’s feet after repeated injections.1 The READY-4 study met its primary and secondary endpoints, with less than one in five participants experiencing treatment-related treatment-emergent adverse events (TEAEs), and all events deemed mild or moderate.1 Efficacy and patient satisfaction were also maintained across multiple treatments.1 The data were presented at the American Society for Dermat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.